Chemische Fabrik Kreussler & CO GmbH   Report issue

Contributed to NME For profit Phase 4
Founded: Wiesbaden Germany (1912)
Status: Left NME R&D (2022)

Organization Overview

First Clinical Trial
2017
NCT03354312
First Marketed Drug
2010
polidocanol (asclera)
First NDA Approval
2010
polidocanol (asclera)
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

CHEMISCHE FABRIK KREUSSLER & CO. | Chemische Fabrik Kreussler & CO GmbH | CHEMISCH FBRK KRSSLR

Active Ingredients

Marketed Drugs (1)

polidocanol (asclera) (2010 NDA)

Drugs in Phase 4 Trials (3)

articaine (Septocaine) (1 trial)

epinephrine (levophed) (1 trial)

lidocaine (xylocaine) (1 trial)

Indications

Approved Indications


 

Esophageal and Gastric Varices

Telangiectasis

Varicose Veins

Venous Insufficiency

Experimental Indications (Clinical Trials, Phases 1-4)


 

Periodontitis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 1
  • # of Trial APIs: 3